✦ LIBER ✦

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

✍ Scribed by Richard M. Stone; Kathleen A. Donohue; Wendy Stock; Vera Hars; Charles A. Linker; Thomas Shea; Daniel J. DeAngelo; Guido Marcucci; Clara D. Bloomfield; Richard A. Larson; for the Cancer and Leukemia Group B

Book ID: 105992958
Publisher: Springer
Year: 2008
Tongue: English
Weight: 281 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0805-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of low-dose continuous in

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

✍ Hagop M. Kantarjian; Michael J. Keating; Ronald S. Walters; Charles A. Koller; K 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB 👁 2 views

Phase I/II study of subcutaneous homohar

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

✍ Alfonso Quintás-Cardama; Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brie 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract ## BACKGROUND. Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon. ## METHODS. A Phase I study was com

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment

A randomized trial of continuous infusio

A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia

✍ Yener Koc; Basak Oyan; Ayse Kars; Gulten Tekuzman; Hande Canpinar; Emin Kansu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML). The objective of this randomized study was to evaluate the impact of mode of administration of MTZ on the response and recurrence rates in newly diagnosed patients wi

Continuous infusion of intermediate-dose

Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: A prospective, multicenter phase II study

✍ Hawk Kim; Jae-Hoo Park; Je-Hwan Lee; Jung-Hee Lee; Young-Don Joo; Won-Sik Lee; S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 3 views

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2